A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra? / Beriplex?]) to Improve Survival in Patients with Traumatic Injury and Acute Major Bleeding
This is a prospective, multicenter, randomized, double-blind, placebocontrolled, parallel-group, large simple trial to investigate the efficacy and safety of a single intravenous (IV) infusion of BE1116 in subjects who have traumatic injury, with confirmed or suspected acute major bleeding and / or predicted to receive a large volume blood product transfusion.
Randomization will be in a 1:1 ratio (BE1116:placebo) and stratified by study site.
Child to Adult
Inclusion Criteria: ~Estimated age > 15 years and weight > 50 kg (110 lbs) ~Traumatic injury with confirmed or suspected acute major bleeding and/or Revised Assessment of Bleeding and Transfusion (RABT) score > 2 ~Activation of massive transfusion protocol Exclusion Criteria: ~Cardiopulmonary resuscitation for < 5 consecutive minutes at any time before enrollment ~Isolated penetrating or blunt cranial injury, or exposed brain matter ~Isolated burns estimated to be > 20% total body surface area or suspected inhalational injury ~Known anticoagulation treatment or a history of a TEE, within the past 3 months.
Memorial Hospital Central
Thomas Schroeppel, MD
Protocol Number: 22-0056
More information available at ClinicalTrials.gov: NCT05568888
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers